While several mechanisms of intrinsic resistance have been reported (8–13), the mechanisms underlying the distinct clinical scenario of limited tumor response followed by earlier tumor progression during initial EGFR TKI treatment are less well defined. This evidence concerns the gene EGFR and neoplasm.